Anaplastic Thyroid Cancer Drugs - Global Market Outlook (2017-2026)
According to Stratistics MRC, the Global Anaplastic Thyroid Cancer Drugs market is accounted for $ 139.56 million in 2017 and is expected to reach $ 231.81 million by 2026 growing at a CAGR of 5.8% during the forecast period. Some of the key factors such as the existence of recompense policy for chemotherapy will include a useful blow which is propelling the growth of the market. However, the charge of this therapeutics is exceptionally high which is hampering the growth of the market.
Anaplastic Thyroid Cancer is the mainly exceptional thyroid cancer, in the main lethal thyroid cancer, and the main complex thyroid cancer to do surgery upon. The accurate operation depends upon the anaplastic thyroid cancer scope of the attack and is merely even measured suitable while there is extremely no proof that there is any remote spread of the infection. The entire anaplastic thyroid cancer is isolated from the neck in the early surgery. imperfect surgery is not correctable.
Based on the treatments available, Chemotherapy is universal treatment, which means that the medicine enters the blood torrent and travels all over the body to arrive at and demolish cancer cells. The Chemotherapy uses anti-cancer drugs to be injected into a layer or engaged by mouth. It is frequently joint with exterior beam radiation therapy for anaplastic thyroid cancer and is occasionally used for other higher cancers that no longer react to other treatments.
By Geography, North America was the maximum returns provider to the global anaplastic thyroid cancer drugs market. It will retain its top place during the forecast period. Anaplastic thyroid cancer is ordinary with adult citizens. Thus, the growing aged population in the region is most important to market growth. Furthermore, the rising quantity of awareness programs, being conducted by vendors and healthcare organizations, are also bolstering the growth of the anaplastic thyroid cancer drugs market in North America.
Some of the key players profiled in the Anaplastic Thyroid Cancer Drugs Market include Pfizer Inc., Daiichi Sankyo Company, Limited, Trophogen, Inc., Plexxikon Inc., Novartis Ag, Millennium Pharmaceuticals Inc, Immune Pharmaceuticals Inc., and Genelux Corporation.
Types Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Anaplastic Thyroid Cancer is the mainly exceptional thyroid cancer, in the main lethal thyroid cancer, and the main complex thyroid cancer to do surgery upon. The accurate operation depends upon the anaplastic thyroid cancer scope of the attack and is merely even measured suitable while there is extremely no proof that there is any remote spread of the infection. The entire anaplastic thyroid cancer is isolated from the neck in the early surgery. imperfect surgery is not correctable.
Based on the treatments available, Chemotherapy is universal treatment, which means that the medicine enters the blood torrent and travels all over the body to arrive at and demolish cancer cells. The Chemotherapy uses anti-cancer drugs to be injected into a layer or engaged by mouth. It is frequently joint with exterior beam radiation therapy for anaplastic thyroid cancer and is occasionally used for other higher cancers that no longer react to other treatments.
By Geography, North America was the maximum returns provider to the global anaplastic thyroid cancer drugs market. It will retain its top place during the forecast period. Anaplastic thyroid cancer is ordinary with adult citizens. Thus, the growing aged population in the region is most important to market growth. Furthermore, the rising quantity of awareness programs, being conducted by vendors and healthcare organizations, are also bolstering the growth of the anaplastic thyroid cancer drugs market in North America.
Some of the key players profiled in the Anaplastic Thyroid Cancer Drugs Market include Pfizer Inc., Daiichi Sankyo Company, Limited, Trophogen, Inc., Plexxikon Inc., Novartis Ag, Millennium Pharmaceuticals Inc, Immune Pharmaceuticals Inc., and Genelux Corporation.
Types Covered:
- Crolibulin
- Efatutazone
- GLONC-2
- CLM-94
- Other Types
- Sorafenib (phase 2)
- Paclitaxel and Pazopanib HCl (phase 2)
- MLN0128 (phase 2)
- Lapatinib Ditosylate and Dabrafenib (phase 1)
- Everolimus (phase 2)
- CS7017 (phase 1)
- Crolibulin (phase 1)
- Cabozantinib (phase 2)
- CA4P (phase 2)
- Bevacizumab (phase 2)
- Other Products
- Surgical Treatments
- Radiation Therapy
- Novel Therapy
- Cryosurgery
- Chemotherapy
- Oral
- Injection
- Clinic
- Hospital
- Other Applications
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
- Competitive Benchmarking
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY TYPE
5.1 Introduction
5.2 Crolibulin
5.3 Efatutazone
5.4 GLONC-2
5.5 CLM-94
5.6 Other Types
6 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY PRODUCT
6.1 Introduction
6.2 Sorafenib (phase 2)
6.3 Paclitaxel and Pazopanib HCl (phase 2)
6.4 MLN0128 (phase 2)
6.5 Lapatinib Ditosylate and Dabrafenib (phase 1)
6.6 Everolimus (phase 2)
6.7 CS7017 (phase 1)
6.8 Crolibulin (phase 1)
6.9 Cabozantinib (phase 2)
6.10 CA4P (phase 2)
6.11 Bevacizumab (phase 2)
6.12 Other Products
7 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY TREATMENTS
7.1 Introduction
7.2 Surgical Treatments
7.3 Radiation Therapy
7.4 Novel Therapy
7.5 Cryosurgery
7.6 Chemotherapy
8 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY METHOD
8.1 Introduction
8.2 Oral
8.3 Injection
9 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY APPLICATION
9.1 Introduction
9.2 Clinic
9.3 Hospital
9.4 Other Applications
10 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY GEOGRAPHY
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.6 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 KEY DEVELOPMENTS
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 COMPANY PROFILING
12.1 Pfizer Inc.
12.2 Daiichi Sankyo Company, Limited
12.3 Trophogen, Inc.
12.4 Plexxikon Inc.
12.5 Novartis AG
12.6 Millennium Pharmaceuticals Inc
12.7 Immune Pharmaceuticals Inc.
12.8 Genelux Corporation
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY TYPE
5.1 Introduction
5.2 Crolibulin
5.3 Efatutazone
5.4 GLONC-2
5.5 CLM-94
5.6 Other Types
6 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY PRODUCT
6.1 Introduction
6.2 Sorafenib (phase 2)
6.3 Paclitaxel and Pazopanib HCl (phase 2)
6.4 MLN0128 (phase 2)
6.5 Lapatinib Ditosylate and Dabrafenib (phase 1)
6.6 Everolimus (phase 2)
6.7 CS7017 (phase 1)
6.8 Crolibulin (phase 1)
6.9 Cabozantinib (phase 2)
6.10 CA4P (phase 2)
6.11 Bevacizumab (phase 2)
6.12 Other Products
7 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY TREATMENTS
7.1 Introduction
7.2 Surgical Treatments
7.3 Radiation Therapy
7.4 Novel Therapy
7.5 Cryosurgery
7.6 Chemotherapy
8 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY METHOD
8.1 Introduction
8.2 Oral
8.3 Injection
9 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY APPLICATION
9.1 Introduction
9.2 Clinic
9.3 Hospital
9.4 Other Applications
10 GLOBAL ANAPLASTIC THYROID CANCER DRUGS MARKET, BY GEOGRAPHY
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.6 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 KEY DEVELOPMENTS
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 COMPANY PROFILING
12.1 Pfizer Inc.
12.2 Daiichi Sankyo Company, Limited
12.3 Trophogen, Inc.
12.4 Plexxikon Inc.
12.5 Novartis AG
12.6 Millennium Pharmaceuticals Inc
12.7 Immune Pharmaceuticals Inc.
12.8 Genelux Corporation
LIST OF TABLES
Table 1 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Type (2016-2026) (US $MN)
Table 3 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (2016-2026) (US $MN)
Table 4 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Efatutazone (2016-2026) (US $MN)
Table 5 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By GLONC-2 (2016-2026) (US $MN)
Table 6 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CLM-94 (2016-2026) (US $MN)
Table 7 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Types (2016-2026) (US $MN)
Table 8 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Product (2016-2026) (US $MN)
Table 9 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Sorafenib (phase 2) (2016-2026) (US $MN)
Table 10 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Paclitaxel and Pazopanib HCl (phase 2) (2016-2026) (US $MN)
Table 11 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By MLN0128 (phase 2) (2016-2026) (US $MN)
Table 12 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Lapatinib Ditosylate and Dabrafenib (phase 1) (2016-2026) (US $MN)
Table 13 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Everolimus (phase 2) (2016-2026) (US $MN)
Table 14 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CS7017 (phase 1) (2016-2026) (US $MN)
Table 15 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (phase 1) (2016-2026) (US $MN)
Table 16 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cabozantinib (phase 2) (2016-2026) (US $MN)
Table17 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CA4P (phase 2) (2016-2026) (US $MN)
Table 18 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Bevacizumab (phase 2) (2016-2026) (US $MN)
Table 19 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Products (2016-2026) (US $MN)
Table 20 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Treatments (2016-2026) (US $MN)
Table 21 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Surgical Treatments (2016-2026) (US $MN)
Table 22 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
Table 23 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Novel Therapy (2016-2026) (US $MN)
Table 24 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cryosurgery (2016-2026) (US $MN)
Table 25 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Chemotherapy (2016-2026) (US $MN)
Table 26 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Method (2016-2026) (US $MN)
Table 27 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Oral (2016-2026) (US $MN)
Table 28 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Injection (2016-2026) (US $MN)
Table 29 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Application (2016-2026) (US $MN)
Table 30 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Clinic (2016-2026) (US $MN)
Table 31 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Hospital (2016-2026) (US $MN)
Table 32 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Applications (2016-2026) (US $MN)
NOTE: Tables for North America, Europe, Asia Pacific, South America, and Middle East & Africa are represented in the same manner above.
Table 1 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Type (2016-2026) (US $MN)
Table 3 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (2016-2026) (US $MN)
Table 4 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Efatutazone (2016-2026) (US $MN)
Table 5 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By GLONC-2 (2016-2026) (US $MN)
Table 6 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CLM-94 (2016-2026) (US $MN)
Table 7 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Types (2016-2026) (US $MN)
Table 8 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Product (2016-2026) (US $MN)
Table 9 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Sorafenib (phase 2) (2016-2026) (US $MN)
Table 10 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Paclitaxel and Pazopanib HCl (phase 2) (2016-2026) (US $MN)
Table 11 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By MLN0128 (phase 2) (2016-2026) (US $MN)
Table 12 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Lapatinib Ditosylate and Dabrafenib (phase 1) (2016-2026) (US $MN)
Table 13 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Everolimus (phase 2) (2016-2026) (US $MN)
Table 14 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CS7017 (phase 1) (2016-2026) (US $MN)
Table 15 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (phase 1) (2016-2026) (US $MN)
Table 16 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cabozantinib (phase 2) (2016-2026) (US $MN)
Table17 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CA4P (phase 2) (2016-2026) (US $MN)
Table 18 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Bevacizumab (phase 2) (2016-2026) (US $MN)
Table 19 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Products (2016-2026) (US $MN)
Table 20 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Treatments (2016-2026) (US $MN)
Table 21 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Surgical Treatments (2016-2026) (US $MN)
Table 22 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
Table 23 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Novel Therapy (2016-2026) (US $MN)
Table 24 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cryosurgery (2016-2026) (US $MN)
Table 25 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Chemotherapy (2016-2026) (US $MN)
Table 26 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Method (2016-2026) (US $MN)
Table 27 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Oral (2016-2026) (US $MN)
Table 28 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Injection (2016-2026) (US $MN)
Table 29 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Application (2016-2026) (US $MN)
Table 30 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Clinic (2016-2026) (US $MN)
Table 31 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Hospital (2016-2026) (US $MN)
Table 32 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Applications (2016-2026) (US $MN)
NOTE: Tables for North America, Europe, Asia Pacific, South America, and Middle East & Africa are represented in the same manner above.
